GlobeNewswire·Nov 5, 2026, 5:00 PM ET

Quantum BioPharma Ltd. Announces Filing of Supplement to Management Information Circular Correcting Fractional Share Treatment Under Proposed Share Consolidation and Clarifies MVS Voting Power Threshold

Quantum BioPharma Ltd. filed a supplement to its September 28, 2026 management information circular regarding the November 10, 2026 shareholder meeting.
The supplement corrects the special resolution authorizing the consolidation of class A multiple voting shares & class B subordinate voting shares.
The correction clarifies that fractional shares resulting from the consolidation will be rounded down if equal to or less than one-half, or rounded up if greater than one-half.
The company will cap the aggregate voting power of class A multiple voting share holders at 70% if cancellations cause their ownership to exceed that threshold.
Existing proxy forms remain valid for the meeting & no amended proxy forms will be distributed.
Shareholders may revoke or change voting instructions by following procedures outlined in the circular or contacting their intermediaries.
Quantum BioPharma is developing treatments for neurodegenerative, metabolic, & alcohol misuse disorders, including its lead compound Lucid-MS.
The company owns 19.48% of Unbuzzd Wellness Inc. & receives 7% royalties on sales until $250 million is reached, after which the rate drops to 3%.
The release contains forward-looking statements regarding the proposed share consolidation & voting power cap, which are subject to risks & uncertainties.